In myeloid malignancies, the MDS cell MDS-L has been found to be resistant to glasdegib, but the inhibition of GLI1 by siRNA-mediated knockdown or the GLI1 antagonist, GANT61, inhibits cell proliferation [38]. This evidence concerns the gene GLI1 and myeloid neoplasm.